T. Rowe Price Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-26,386
| Closed | -$490K | – | 2958 |
|
|
2023
Q3 | $490K | Buy |
26,386
+4,423
| +20% | +$50K | ﹤0.01% | 2115 |
|
|
2023
Q2 | $243K | Buy |
21,963
+384
| +2% | +$5.35K | ﹤0.01% | 2458 |
|
|
2023
Q1 | $290K | Buy |
21,579
+143
| +0.7% | +$2.47K | ﹤0.01% | 2360 |
|
|
2022
Q4 | $265K | Buy |
21,436
+466
| +2% | +$6.6K | ﹤0.01% | 2421 |
|
|
2022
Q3 | $293K | Buy |
20,970
+1,446
| +7% | +$23.3K | ﹤0.01% | 2392 |
|
|
2022
Q2 | $270K | Sell |
19,524
-1,367
| -7% | -$21.9K | ﹤0.01% | 2483 |
|
|
2022
Q1 | $340K | Sell |
20,891
-6,523
| -24% | -$102K | ﹤0.01% | 2504 |
|
|
2021
Q4 | $447K | Buy |
+27,414
| New | +$462K | ﹤0.01% | 2440 |
|
|
2020
Q3 | – | Sell |
-420,459
| Closed | -$20.1M | – | 2638 |
|
|
2020
Q2 | $20.1M | Sell |
420,459
-128,423
| -23% | -$9.92M | ﹤0.01% | 1147 |
|
|
2020
Q1 | $34.6M | Sell |
548,882
-100,102
| -15% | -$9M | 0.01% | 902 |
|
|
2019
Q4 | $80.4M | Buy |
648,984
+455,805
| +236% | +$40.8M | 0.01% | 742 |
|
|
2019
Q3 | $12.8M | Sell |
193,179
-1,394
| -0.7% | -$93.6K | ﹤0.01% | 1250 |
|
|
2019
Q2 | $15.5M | Sell |
194,573
-1,735
| -0.9% | -$155K | ﹤0.01% | 1245 |
|
|
2019
Q1 | $22M | Buy |
196,308
+188,961
| +2,572% | +$20.6M | ﹤0.01% | 1153 |
|
|
2018
Q4 | $741K | Sell |
7,347
-501
| -6% | -$51.9K | ﹤0.01% | 1924 |
|
|
2018
Q3 | $992K | Buy |
7,848
+2,547
| +48% | +$270K | ﹤0.01% | 1884 |
|
|
2018
Q2 | $445K | Buy |
5,301
+97
| +2% | +$7.1K | ﹤0.01% | 2190 |
|
|
2018
Q1 | $320K | Sell |
5,204
-3,549
| -41% | -$214K | ﹤0.01% | 2273 |
|
|
2017
Q4 | $511K | Buy |
8,753
+3,806
| +77% | +$240K | ﹤0.01% | 2083 |
|
|
2017
Q3 | $287K | Sell |
4,947
-14,394
| -74% | -$1.55M | ﹤0.01% | 2299 |
|
|
2017
Q2 | $2.34M | Sell |
19,341
-974
| -5% | -$113K | ﹤0.01% | 1523 |
|
|
2017
Q1 | $2.3M | Sell |
20,315
-90,400
| -82% | -$10.6M | ﹤0.01% | 1542 |
|
|
2016
Q4 | $12M | Buy |
110,715
+999
| +0.9% | +$119K | ﹤0.01% | 1280 |
|
|
2016
Q3 | $18.1M | Buy |
109,716
+86,931
| +382% | +$13.7M | ﹤0.01% | 1172 |
|
|
2016
Q2 | $3.25M | Sell |
22,785
-800
| -3% | -$117K | ﹤0.01% | 1452 |
|
|
2016
Q1 | $3.03M | Sell |
23,585
-314,171
| -93% | -$37.1M | ﹤0.01% | 1460 |
|
|
2015
Q4 | $50.4M | Sell |
337,756
-1,750
| -0.5% | -$296K | 0.01% | 763 |
|
|
2015
Q3 | $56.3M | Buy |
339,506
+11,203
| +3% | +$2.46M | 0.01% | 735 |
|
|
2015
Q2 | $79.2M | Sell |
328,303
-76,784
| -19% | -$20.4M | 0.02% | 675 |
|
|
2015
Q1 | $114M | Buy |
405,087
+148,885
| +58% | +$32.2M | 0.02% | 570 |
|
|
2014
Q4 | $40M | Sell |
256,202
-6,384
| -2% | -$1.18M | 0.01% | 913 |
|
|
2014
Q3 | $62.2M | Sell |
262,586
-359,444
| -58% | -$91.6M | 0.01% | 757 |
|
|
2014
Q2 | $147M | Buy |
622,030
+54,390
| +10% | +$14.3M | 0.03% | 519 |
|
|
2014
Q1 | $187M | Buy |
+567,640
| New | +$192M | 0.04% | 448 |
|
T. Rowe Price Associates's ICPT Position: Q4 2023 in Review
T. Rowe Price Associates sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 26,386 shares — an estimated $490K sold.
T. Rowe Price Associates first reported a position in ICPT in Q1 2014 and held it in 34 quarters. The position peaked at $187M in Q1 2014. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- T. Rowe Price Associates reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- T. Rowe Price Associates sold 26,386 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $490K.
- T. Rowe Price Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 34 quarters.
- T. Rowe Price Associates's Intercept Pharmaceuticals, Inc. position peaked at $187M in Q1 2014.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.